Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GALE $2.29 0.2100 +10.10%
EPZM $23.35 1.6900 +7.80%
SPPI $7.18 0.2800 +4.06%
BDSI $8.66 0.1900 +2.24%
NYMX $5.24 0.0900 +1.75%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PARD $0.21 -0.1099 -34.34%
IMNP $3.96 -0.5300 -11.80%
TGTX $5.16 -0.6600 -11.34%
IMMU $4.15 -0.4200 -9.19%
GERN $2.00 -0.1900 -8.68%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

ASCO Releases First Three Guidelines on Cancer Survivorship Care

(ASCO) Apr 14, 2014 - The American Society of Clinical Oncology (ASCO) today issued three evidence-based clinical practice guidelines on the prevention and management of symptoms that affect many cancer survivors—neuropathy, fatigue and depression, and anxiety.
read press release 

NICE Nod for Firmagon's Prostate Cancer Drug

(PharmaTimes [UK]) Apr 15, 2014 - A subgroup of patients with advanced prostate cancer could now get access to a new treatment option in England and Wales after cost regulators for the NHS issued a green light for Ferring's Firmagon (degarelix).
read article 

BioAlliance Pharma Announces a New Positive DSMB Recommendation to Continue Its Phase III Clinical Trial with Livatag® in Primary Liver Cancer

(Yahoo! Finance) Apr 14, 2014 - BioAlliance Pharma SA today announced that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB), in charge of the safety profile of the ReLive Phase III trial, today held its fourth meeting and once more unanimously recommended continuing the study without modification.
read article 

UK Drug Company Glaxo 'Paid Bribes to Polish Doctors'

(BBC News) Apr 13, 2014 - UK drug company GlaxoSmithKline is facing a criminal investigation in Poland for allegedly bribing doctors, BBC Panorama has discovered.
read article 

Intercept's Liver Disease Drug Proves Highly Effective in Study

(Reuters) Apr 12, 2014 - A drug being developed by Intercept Pharmaceuticals Inc led to significant improvement in signs of a rare liver disease that primarily affects middle-aged women, likely reducing the risk of need for liver transplant and of death, according to results of a late-stage clinical trial presented on Saturday.
read article 

Liver Drug at $84,000 Not So Pricey Because It Works, Fast

(Washington Post/Bloomberg) Apr 14, 2014 - While the $84,000 price of Gilead Sciences Inc.’s Sovaldi has riled lawmakers and public health advocates, doctors say this new generation of hepatitis C drugs may actually help cut costs.
read article (free registration required) 

Lawyers Start Mining the Medicare Data for Clues to Fraud

(Reuters) Apr 14, 2014 - Within hours of the U.S. government's unprecedented release last week of a trove of Medicare billing data, a small fraternity of lawyers who specialize in representing whistleblowers in healthcare fraud cases began to mobilize.
read article 

5 Things to Know About Morcellation

(Wall Street Journal [blog]) Apr 11, 2014 - Morcellaton is the subject of a page-one story; here are five things to know:
read article (paid subscription required) 

FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?

(TheStreet) Apr 11, 2014 - Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.
read article 

Commission Suggests Improvements to Cancer Care in China, India and Russia

(Medical News Today) Apr 12, 2014 - The Lancet Oncology published the findings of a special commission formed to analyze the quality of cancer care in three large countries that present major health care challenges.
read article 

UC Davis Personalizing Outreach to Address Asian Cancer Health Disparities

(UC Davis Health System) Apr 11, 2014 - In an effort to reduce cancer health disparities among Asian-Americans, UC Davis Comprehensive Cancer Center now offers individual, in-language education and culturally sensitive materials for every Asian-American cancer patient.
read press release 

Device That Prevents Chemo-related Hair Loss for Breast Cancer Patients May Become Available in U.S.

(New York Daily News) Apr 13, 2014 - The DigniCap, a Swedish device that has been successfully used in Europe since 1999, but is not used in the United States, may become available in 2015.
read article 

Physicians With Fox Valley Hematology & Oncology Join Illinois Cancer Specialists

(The US Oncology Network) Apr 14, 2014 - Illinois Cancer Specialists (ICS) announced today that the physicians with Fox Valley Hematology & Oncology (FVHO) will join its oncology and hematology practice to expand and enhance patient services in Chicago and the Northwest suburbs.
read corporate press release 

Dying Patients Denied Drugs

(CNN) Apr 6, 2014 - At first, Sandy Barker decided to behave nicely and sit silently in the audience as an official from the Food and Drug Administration extolled the virtues of a program to get experimental drugs to desperately ill patients. Then she couldn't take it anymore.
read article 

Letters: Payment Numbers Give Unclear View of Oncologists’ Challenges

(Boston Globe) Apr 14, 2014 - Regarding the article on Medicare payments to physicians (“30 doctors in state got $45m from Medicare”): The published payment numbers do not separate out reimbursement for procuring medicines and services from physician income.
read article (free registration required) 

Letters: Data Dump on Payments Does More Harm Than Good

(Boston Globe) Apr 14, 2014 - Oncologists have been singled out for high levels of reimbursement, but more context is needed.
read article (free registration required) 

ASH Contributes to American College of Physicians’ High Value Care Coordination Toolkit

(ASH) Apr 11, 2014 - The American Society of Hematology (ASH) took a meaningful step toward helping facilitate more effective and patient-centered communication between primary care doctors and hematologists through a contribution to a new American College of Physicians (ACP) resource.
read press release 

Value of PSA Screening Assessed at World Chinese Joint Session

(EAU) Apr 11, 2014 - As part of the World Chinese Joint Session, organized for the very first time at the EAU Congress, the advantages and disadvantages of PSA screening for prostate cancer were discussed from the European and Asian perspectives.
read article 

Dutch Expert: PSA Screening Is Here to Stay Despite Debate

(EAU) Apr 11, 2014 - Despite the continuing debate regarding the harms and benefits of PSA screening, prostate cancer experts from the Netherlands are convinced that PSA screening “is here to stay.”
read article 

First Joint EAU-SIU Session Focuses on Urothelial Carcinoma

(EAU) Apr 11, 2014 - The first joint session of the European Association of Urology (EAU) and the Société Internationale d’Urologie (SIU) discussed risk stratification, conservative management and surgical approaches to urothelial carcinomas, with lively discussion and enthusiastic participation from the audience.
read article 

Swedish Researchers Win Best Abstract in Oncology

(EAU) Apr 12, 2014 - A group of Swedish researchers have won the first prize for Best Abstract in Oncology for their work on the classification of T1 bladder cancer which aims to identify high-risk subtypes using marker genes.
read article 

Professional Groups: A Key Role in Boosting Prostate Cancer Research

(EAU) Apr 13, 2014 - Professional medical groups, particularly those operating in international and regional levels, play a vital role in boosting cancer research with future trends expected to emphasise intra-regional collaborations and international initiatives.
read article 

ESOU: Debating the Best Approach to Radical Prostatectomy and Cystectomy

(EAU) Apr 12, 2014 - One of the biggest themes during the meeting of the EAU Section of Oncological Urology (ESOU) was the comparison between robot-assisted radical prostatectomy and cystectomy to open surgery. Cost-effectiveness was an important factor in the discussion.
read article 

Radical Cystectomy: Still the Recommended Treatment?

(EAU) Apr 13, 2014 - "Radical cystectomy is the treatment of choice for patients with muscle-invasive bladder cancer,” Prof. George Thalmann summarized at the end of a debate that pitted cystectomy against bladder-preserving alternatives.
read article 

Thematic Session 10: Update on Treatment Options for Patients with CRPC

(EAU) Apr 14, 2014 - There are new treatment options for castration resistant prostate cancer (CRPC) but finding the optimal strategy and selecting the right patient is still fraught with challenges and difficulties, according to uro-oncology experts during a thematic session at the 29th Annual EAU Congress in Stockholm, Sweden.
read article